Grifols (NASDAQ:GRFS) Upgraded by Wall Street Zen to Buy Rating

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Friday.

Separately, Morgan Stanley began coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Stock Down 0.7%

GRFS stock opened at $8.13 on Friday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The firm's 50-day simple moving average is $7.31 and its 200 day simple moving average is $7.62. The stock has a market cap of $5.59 billion, a PE ratio of 6.95 and a beta of 0.44.

Hedge Funds Weigh In On Grifols

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its position in Grifols by 5.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after buying an additional 1,657 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Grifols by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 46,078 shares of the biotechnology company's stock valued at $328,000 after buying an additional 2,026 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Grifols by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock worth $192,000 after purchasing an additional 2,403 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Grifols by 14.9% in the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Grifols in the fourth quarter worth approximately $28,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.